BPOM in Process of Approving Sinovac Doses for Children Aged 3

TEMPO.CO, Jakarta - The Food and Drugs Monitoring Agency (BPOM) is currently processing the emergency use authorization (EUA) for the primary dose of the Covid-19 Sinovac vaccine for children aged 3 and above. 

Antaranews reported, that the BPOM has approved three coronavirus vaccine brands for children as primary doses or boosters. These brands include Sinovac for those aged 6 and above; Pfizer for children over 12; and Covovax for the 12-year-old and above. 

Of the three types of vaccines for the primary dose, only Pfizer has been approved for use for homologous boosters (primary vaccine recipients who also received Pfizer), namely in children aged 16 to 18 years. Only Pfizer has been approved for use as a booster vaccine for children globally.

BPOM Head Penny K. Lukito revealed this in a House hearing session at Commission IX of the Indonesian House of Representatives in Jakarta, Tuesday, August 30. 

"There is one new booster approved for children by the United States and the United Arab Emirates, namely Pfizer for ages 5-17. year," she said.

Domestically-made Covid-19 vaccine candidates are also directed at children. This can be seen from Penny's statement on the Inavac vaccine produced by the team at Airlangga University (Unair) and PT Biotis, as well as the Indovac vaccine or more often referred to as the BUMN vaccine from Bio Farma.

"BPOM is in the process of submitting a clinical trial protocol for domestically produced vaccines for children," said Penny who also explained that the Inavac vaccine is for ages 6-11 years and is currently entering the final clinical trial phase

ANTARA

Click here to get the latest news updates from Tempo on Google News